8-K: Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

Chimerix announced its third quarter 2024 financial results, provided an operational update on its clinical programs, and highlighted the promotion of a new Chief Scientific Officer.

Summary

• Chimerix reported a net loss of $22.9 million for the third quarter of 2024, compared to a net loss of $24.0 million for the same period in 2023.
• Research and development expenses increased to $19.6 million, while general and administrative expenses decreased to $5.2 million for the quarter.
• The company has $152.4 million in capital available to fund operations as of September 30, 2024, with no outstanding debt.
• The Phase 3 ACTION study for dordaviprone is on track, with interim overall survival data expected in the third quarter of 2025.
• The Independent Data Monitoring Committee (IDMC) recommended continuing the ACTION study as-is following a preplanned safety review.
• Chimerix has alignment with the Therapeutic Goods Administration (TGA) to submit dordaviprone for provisional approval in Australia, with potential commercial availability by year-end 2025.
• Enrollment in a Phase 1 dose escalation study of ONC206 is expected to be completed in 2024, with assessment of objective responses expected in the first half of 2025.
• Dr. Josh Allen was promoted to Chief Scientific Officer in September 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and regulatory pathways, but also acknowledges the financial challenges of a clinical-stage company. The positive clinical data and regulatory progress are balanced by the ongoing losses and risks associated with drug development.

Positives

• The Phase 3 ACTION study is progressing as planned, with a clear timeline for interim data.
• The IDMC's recommendation to continue the study without changes is a positive sign for the safety profile of dordaviprone.
• Alignment with the TGA for provisional approval in Australia provides a potential pathway for early commercialization.
• The company has a strong cash position with $152.4 million available to fund operations.
• ONC206 is showing promising safety and pharmacokinetic data in early trials.
• The promotion of Dr. Josh Allen to Chief Scientific Officer is a positive move, given his expertise in the company's core technology.
• Dordaviprone has shown clinically meaningful efficacy in recurrent H3 K27M-mutant DMG with a 30% overall response rate.
• ONC206 has shown monotherapy activity in multiple non-clinical CNS models as well as tumors outside the CNS.

Negatives

• The company reported a net loss of $22.9 million for the third quarter of 2024.
• Research and development expenses increased to $19.6 million for the quarter.
• The company is still in the clinical trial phase and has not yet achieved commercial sales of its products.

Risks

• The success of the Phase 3 ACTION study is critical for the future of dordaviprone, and there is a risk that the results may not be positive.
• Regulatory approval in Australia is not guaranteed, and there may be delays or challenges in the process.
• Clinical trials for ONC206 are still in early stages, and there is a risk that the drug may not be effective or safe.
• The company is dependent on external funding and may need to raise additional capital in the future.
• The company is subject to risks related to the ability to obtain and maintain accelerated approval.
• There are risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies.

Future Outlook

The company expects to complete enrollment in the ONC206 Phase 1 dose escalation study in 2024 and assess objective responses in the first half of 2025. They also anticipate submitting dordaviprone for provisional approval in Australia in the coming months, with potential commercial availability by year-end 2025. The company is also looking at future development scenarios for ONC206.

Management Comments

• Mike Andriole, Chief Executive Officer of Chimerix, stated that they have sustained execution of the Phase 3 ACTION study and are encouraged by the safety profile of dordaviprone.
• Mike Andriole also mentioned that they have alignment with the TGA to file a New Drug Application (NDA) for Provisional Approval in Australia.
• Mr. Andriole expressed delight in announcing the promotion of Dr. Josh Allen to the role of Chief Scientific Officer.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for rare and aggressive cancers. The focus on H3 K27M-mutant diffuse glioma addresses a high unmet medical need, and the progress of dordaviprone is being closely watched by the neuro-oncology community. The development of ONC206 also positions Chimerix in the broader field of cancer therapeutics.

Comparison to Industry Standards

• The median overall survival of 13.7 months for dordaviprone in Phase 2 trials is significantly higher than the 5.1 months observed in historical controls, suggesting a potential breakthrough in the treatment of H3 K27M-mutant diffuse glioma.
• The 30% overall response rate for dordaviprone in recurrent H3 K27M-mutant DMG is also notable, as this is a difficult-to-treat cancer with limited effective therapies.
• The safety profile of ONC206 appears to be consistent with other early-stage oncology drugs, with most treatment-related adverse events being mild to moderate.
• The company's cash position of $152.4 million is relatively strong for a company of its size and stage of development, providing a runway for continued clinical development.
• Compared to companies like Kura Oncology and Day One Biopharmaceuticals, which are also developing targeted cancer therapies, Chimerix is focused on a specific mutation and has a clear path to potential regulatory approval in Australia.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the progress of the clinical programs and the potential for regulatory approval.
• Employees may be motivated by the company's progress and the promotion of Dr. Allen.
• Patients with H3 K27M-mutant diffuse glioma may have hope for a new treatment option.
• The company's suppliers and partners may benefit from the continued development of its products.

Next Steps

• Chimerix will continue enrolling patients in the Phase 3 ACTION study for dordaviprone.
• The company will submit a New Drug Application (NDA) for Provisional Approval of dordaviprone in Australia.
• Chimerix will complete enrollment in the Phase 1 dose escalation study of ONC206.
• The company will assess objective responses in patients in the ONC206 dose escalation study in the first half of 2025.
• Chimerix will continue nonclinical studies for ONC206 to identify candidate oncology indications and biomarkers.

Key Dates

Keywords

dordaviprone, ONC201, ONC206, H3 K27M-mutant glioma, ACTION study, clinical trials, biopharmaceutical, cancer, CNS tumors, imipridone, TGA, orphan drug designation